Good morning, everyone, and welcome to another working week. We hope the weekend respite was restful and invigorating, because that predictable routine of online meetings and deadlines has returned. But what can you do? After all, the world, such as it is, keeps spinning. So time to pick up a cup of stimulation and give it a little nudge. Our choice today is blueberry. Please feel free to join us. Meanwhile, here are a few tidbits to help you on your journey. We hope all goes well today and you conquer the world. And of course, do stay in touch. …
Ten House Democrats fired a warning shot in the spring that they could cause trouble for House Speaker Nancy Pelosi’s signature drug pricing reform legislation. But as the House prepares to vote on a multitrillion-dollar spending bill that appears likely to include those drug pricing policies, it is almost impossible to imagine all 10 voting against the entire package, STAT explains. Already, two lawmakers have actually endorsed the policy. Several others downplayed their objections to it. Pelosi’s top deputies say they are confident moderates wouldn’t dare vote against the larger package, even if they have concerns with the drug-pricing portion.
Pfizer (PFE) has started a mid-to-late-stage study testing its investigational oral antiviral drug for preventing Covid-19 infection among those who have been exposed to the virus, Reuters writes. Pfizer, Merck (MRK), and Roche (RHHBY) are racing to develop the first antiviral pill for the coronavirus. Pfizer plans to study the drug in up to 2,660 healthy participants aged 18 and older who live in the same household as an individual with a confirmed symptomatic Covid-19 infection. The trial would test the drug, known as PF-07321332, with a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
